1. van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol 2000,
67(1):2-17.
2. Eliopoulos AG, Young LS: The role of the CD40 pathway in the
pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004,
4(4):360-7.
3. Challa A, Eliopoulos AG, Holder MJ, Burguete AS, Pound JD, Chamba A,
Grafton G, Armitage RJ, Gregory CD, Martinez-Valdez H, Young L, Gordon J:
Population depletion activates autonomous CD154-dependent survival
in biopsy like Burkitt lymphoma cells. Blood 2002, 99(9):3411-8.
4. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Terry N, Reid PS, Ford RJ: A
CD40 Signalosome anchored in lipid rafts leads to constitutive
activation of NF-kappaB and autonomous cell growth in B cell
lymphomas. Immunity 2002, 16(1):37-50.
5. Baxendale AJ, Dawson CW, Stewart SE, Mudaliar V, Reynolds G, Gordon J,
Murray PG, Young LS, Eliopoulos AG: Constitutive activation of the CD40
pathway promotes cell transformation and neoplastic growth. Oncogene
2005, 24(53):7913-23.
6. Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P,
Gordon J, Selby PJ, Trejdosiewicz LK: The effects of malignant
transformation on susceptibility of human urothelial cells to
CD40-mediated apoptosis. J Natl Cancer Inst 2002, 94(18):1381-95.
7. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J,
Trejdosiewicz LK: A novel mechanism of CD40-induced apoptosis of
carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death
Differ 2006, 13(10):1789-801.
8. Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG: Inhibition of
phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein
synthesis reveals the pro-apoptotic properties of CD40 ligation in
carcinoma cells. J Biol Chem 2004, 279(2):1010-9.
9. He TC, Zhou S, et al: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA 1998, 95(5):2509-14.
10. Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an
overview. Front Biosci 2006, 11:1696-701.
11. Knox PG, Milner AE, et al: Inhibition of metalloproteinase cleavage
enhances the cytotoxicity of Fas ligand. J Immunol 2003, 170(2):677-85.
12. Graf D, Muller S, et al: A soluble form of TRAP (CD40 ligand) is rapidly
released after T cell activation. Eur J Immunol 1995, 25(6):1749-54.
13. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P,
Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY: Recombinant
soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995,
270:7025-7028.
14. Heise C, Hermiston T, et al: An adenovirus E1A mutant that demonstrates
potent and selective systemic anti-tumoral efficacy. Nat Med 2000,
6(10):1134-9.
15. Afford SC, Randhawa S, et al: CD40 activation induces apoptosis in
cultured human hepatocytes via induction of cell surface fas ligand
expression and amplifies fas-mediated hepatocyte death during allograft
rejection. J Exp Med 1999, 189(2):441-6.
16. Eliopoulos AG, Dawson CW, et al: CD40-induced growth inhibition in
epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1:
involvement of TRAF3 as a common mediator. Oncogene 1996,
13(10):2243-54.
17. Eliopoulos AG, Davies C, et al: CD40 induces apoptosis in carcinoma cells
through activation of cytotoxic ligands of the tumor necrosis factor
superfamily. Mol Cell Biol 2000, 20(15):5503-15.
18. Dyson N, Guida P, et al: Adenovirus E1A makes two distinct contacts with
the retinoblastoma protein. J Virol 1992, 66(7):4606-11.
19. Fattaey AR, Harlow E, et al: Independent regions of adenovirus E1A are
required for binding to and dissociation of E2F-protein complexes. Mol
Cell Biol 1993, 13(12):7267-77.
20. Berkner KL, Sharp PA: Generation of adenovirus by transfection of
plasmids. Nucleic Acids Res 1983, 11(17):6003-20.
21. Kelly TJ Jr, Lewis AM Jr: Use of nondefective adenovirus-simian virus 40
hybrids for mapping the simian virus 40 genome. J Virol 1973,
12(3):643-52.
22. Flint SJ, Wewerka-Lutz Y, et al: Adenovirus transcription. II. RNA sequences
complementary to simian virus 40 and adenovirus 2DNA in AD2+ND1-
and AD2+ND3-infected cells. J Virol 1975, 16(3):662-73.
23. Wold WS, Deutscher SL, Takemori N, Bhat BM, Magie SC: Evidence that
AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA
region E3 of adenovirus. Virology 1986, 148(1):168-80.
24. Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT,
Martinon F, Tschopp J, Gooding LR, Ware CF: Three adenovirus E3
proteins cooperate to evade apoptosis by tumor necrosis factor-related
apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 2001,
276(5):3270-8.
25. Wold WS, Doronin K, Toth K, Kuppuswamy M, Lichtenstein DL, Tollefson AE:
Immune responses to adenoviruses: viral evasion mechanisms and their
implications for the clinic. Curr Opin Immunol 1999, 11(4):380-6.
26. Liu Y, Xia D, et al: Intratumoral administration of immature dendritic cells
following the adenovirus vector encoding CD40 ligand elicits significant
regression of established myeloma. Cancer Gene Ther 2005, 12(2):122-32.
27. Kikuchi T, Miyazawa N, et al: Tumor regression induced by intratumor
administration of adenovirus vector expressing CD40 ligand and naive
dendritic cells. Cancer Res 2000, 60(22):6391-5.
28. Tomihara K, Kato K, et al: Gene transfer of CD40-ligand to dendritic cells
stimulates interferon-gamma production to induce growth arrest and
apoptosis of tumor cells. Gene Ther 2008, 15(3):203-13.
29. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S,
Kornek M, Vogt A, Yildiz Y, Sievers E, Schmidt-Wolf IG, Caselmann WH,
Sauerbruch T, Schmitz V: CD40ligand-expressing dendritic cells induce
regression of hepatocellular carcinoma by activating innate and
acquired immunity in vivo. Hepatology 2008, 48(1):157-68.